Lombard Medical Reports 2-Yr Follow-Up Data From Aorfix PYTHAGORAS Pivotal Trial

(RTTNews) - Lombard Medical, Inc. (EVAR), a medical device company focused on Endovascular Aneurysm Repair or EVAR of abdominal aortic aneurysms or AAAs, presented efficacy and safety data from the two-year follow up of the U.S. PYTHAGORAS pre-marketing approval or PMA trial of Aorfix, the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees.

The data, presented by Mark Fillinger, M.D., principal investigator of the Aorfix PYTHAGORAS trial, Director of Vascular Surgery Training Programs, and Professor of Surgery at Geisel School of Medicine, Dartmouth, at the VEITHsymposium, demonstrated 100% freedom from aneurysm rupture, 98% freedom from Type I & III endoleaks and 99% freedom from device migration in patients with a 60 to 90 degree aortic neck angulation, a group typically considered difficult-to-treat and associated with poor treatment outcomes. The VEITHsymposium is being held at the New York Hilton-Midtown in New York City on November 18th - 22nd.

The company said the other key findings from the two-year data comprised 98.2% freedom from AAA-related mortality and 97.2% freedom from graft occlusion in patients with neck angles between 60 to 90 degrees.